Anti-MAG Antibody Neuropathy Treated Successfully with Pomalidomide and Dexamethasone: A Case Report

Read full text Summarise with VIRAT
Authors: Shilpa Gupta, Satish Wagh
Cited by: 0
References: 12

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Anti-myelin-associated glycoprotein (MAG) neuropathy is a rare, immune-mediated demyelinating condition.It is characterised by an association with an IgM monoclonal gammopathy and the presence of pathogenic anti-MAG antibodies.Research into this field began in the 1980s.Initial therapeutic approaches aimed to reduce the M protein concentration using treatments such as plasma exchange, steroids, chlorambucil, azathioprine and cyclophosphamide.Some patients experienced partial benefit, indicating that mechanisms beyond damage solely caused by elevated M protein are involved.Consequently, immune-directed therapies, such as IVIg and rituximab, have demonstrated some efficacy in this patient group.Some case reports suggested the use of Lenalidomide as a potential therapeutic option.This is the first case report showing the successful use of pomalidomide in anti-MAG neuropathy.

Fields of Study & Subjects

Peripheral Neuropathies and Disorders Autoimmune Neurological Disorders and Treatments Multiple Sclerosis Research Studies

Publication details

Journal / source
Journal of Medicine and Medical Studies
Volume
3
Issue
1
Pages
267–269
Publication date
31 March 2026
Language
EN